Akero Therapeutics, Inc(NASDAQ:AKRO) 
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protec...
Website: http://www.akerotx.com
Founded: 2017
IPO Price: $16 (Jun 20, 2019)
Full Time Employees: 16
CEO: Andrew Cheng
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 38.86
H 39.99
L 36.69
C 36.73
V 1,541,115
10EMA 36.73
20EMA 36.73
60EMA 36.73
120EMA 36.73
250EMA 36.73